Kinnate Biopharma Inc (KNTE) Stock
KNTE is no longer traded. Kinnate Biopharma Inc was delisted from the Nasdaq in April 2024.
Prices on this page are historical; the last trade was April 2, 2024 at $2.65.
Kinnate Biopharma Inc stock price history
KNTE final trading statistics
- Final close
- $2.65
- Final trading day
- Apr 2, 2024
- Market cap at delisting
- $124.99M
- Shares outstanding
- 47.17M
- Final 52-week range
- $1.04 – $7.18
- Avg. volume (final 3 mo.)
- 411,846
- All-time high (split-adj.)
- $45.25 · Dec 2020
- All-time low (split-adj.)
- $1.07 · Oct 2023
- Return since IPO
- -93.2%
- Beta
- 1.34
- Book value / share
- $3.66
- Price / book
- 0.72
Kinnate Biopharma Inc annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $0.00 | -$112.6M | -$2.42 |
| FY2022 | $0.00 | -$114.0M | -$2.65 |
| FY2021 | $0.00 | -$89.4M | -$2.06 |
| FY2020 | $0.00 | -$35.4M | -$1.30 |
| FY2019 | $0.00 | -$11.9M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Kinnate Biopharma Inc
Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
Kinnate Biopharma Inc stock FAQ
What happened to Kinnate Biopharma Inc stock?
Kinnate Biopharma Inc stock was delisted from the Nasdaq. Its final close was $2.65 on April 2, 2024.
Is KNTE stock still trading?
No. KNTE was delisted from the Nasdaq in April 2024 and no longer trades on a U.S. exchange.
What was the last price of KNTE stock?
KNTE closed at $2.65 on its final trading day, April 2, 2024, for a market value of about $124.99M.
What were Kinnate Biopharma Inc's revenue and earnings in its last full fiscal year?
Kinnate Biopharma Inc reported revenue of $0.00 and net income of -$112.6M in fiscal 2023, its last full year as a public company.
When did Kinnate Biopharma Inc go public?
Kinnate Biopharma Inc stock began trading on December 3, 2020.